Back to Journals » OncoTargets and Therapy » Volume 9

High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy

Authors Wang C, Fu X, Cai X, Wu X, Hu X, Fan M, Xiang J, Zhang Y, Chen H, Jiang G, Zhao K

Received 30 May 2015

Accepted for publication 20 November 2015

Published 30 December 2015 Volume 2016:9 Pages 117—122


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Daniele Santini

Chunyu Wang,1,2 Xiaolong Fu,3 Xuwei Cai,3 Xianghua Wu,4 Xichun Hu,4 Min Fan,1,2 Jiaqing Xiang,5 Yawei Zhang,5 Haiquan Chen,5 Guoliang Jiang,1,2 Kuaile Zhao1,2

1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 2Department of Oncology, Shanghai Medical College, Fudan University, 3Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, 4Department of Medical Oncology, 5Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China

Abstract: Nimotuzumab (h-R3) is a humanized monoclonal antibody that is safe to use against epidermal growth factor receptor (EGFR). However, the available information is insufficient about the dose effect of monoclonal antibody against epidermal growth factor receptor for the treatment of esophageal squamous cell carcinoma (ESCC). We retrospectively recruited 66 patients with ESCC who were treated with h-R3 and chemoradiotherapy/radiotherapy. Patients who received more than 1,200 mg of h-R3 were classified as the high-dose group, and the remaining patients were classified as the low-dose group. The endpoint for efficacy was the overall survival. Differences in survival between the groups were analyzed using the log-rank test. The Cox proportional hazards model was used in multivariate analysis to identify independent prognostic factors. The low-dose and high-dose groups comprised 55 and eleven patients, respectively. The median follow-up time in the final analysis was 46 months. The high-dose group showed no increased incidence of toxicities compared to the low-dose group. The 1-, 2-, and 5-year overall survival rates in the low-dose and high-dose groups were 66.9%, 50.0%, 31.5% and 90.0%, 80.0%, 66.7%, respectively (P=0.04). Multivariate analyses showed that the high-dose group had better survival than the low-dose group (hazard ratio 0.28, 95% confidence interval 0.09–0.94, P=0.039). Taken together, high-dose h-R3 showed limited toxicity and improved survival in patients with ESCC.

Keywords: esophageal squamous cell carcinoma, epidermal growth factor receptor, monoclonal antibody, nimotuzumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]